Among 373 elderly patients diagnosed as advanced NSCLC from January 2018 to December 2020 in our hospital, 212 were tested without targetable oncogene alterations (EGFR/ALK/ROS-1) (Figure 1). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.